2026/02/06 by T. Zuberbier, Z. Abdul Hameed Ansari, A. H. Abdul Latiff +253 · 32 citations
Immunology and Microbiology · Medicine · #Allergy #Angioedema #Chronic urticaria #Coagulation, Bradykinin, Polyphosphates, and Angioedema #European union #Excellence #Grading (engineering) #Guideline #MEDLINE #Mast cells and histamine #Urticaria and Related Conditions
paper · doi:10.1111/all.70210
published in Allergy (Wiley)
openalex publication_date 2026/02/06 · openalex created_date 2026/02/07 · openalex updated_date 2026/08/05
ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA 2 LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), with the participation of 210 delegates from 107 national and international societies, from 59 countries. The consensus conference was held on December 6th, 2024. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell‐driven disease, defined by a rapid appearance of wheals, angioedema, or both. The lifetime prevalence of acute urticaria is estimated to be approximately 20%. Chronic urticaria, categorized as either chronic spontaneous urticaria or chronic inducible urticaria, is disabling, impairs quality of life, and affects performance at work and school, however, novel therapies are available. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert‐guided and evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria.